Sulfanitran

DB11463

small molecule vet_approved

Deskripsi

Struktur Molekul 2D

Berat 335.33
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

113 Data
Nicotine The risk or severity of adverse effects can be increased when Sulfanitran is combined with Nicotine.
Mecamylamine The risk or severity of adverse effects can be increased when Sulfanitran is combined with Mecamylamine.
Pentolinium The risk or severity of adverse effects can be increased when Sulfanitran is combined with Pentolinium.
Trimethaphan The risk or severity of adverse effects can be increased when Sulfanitran is combined with Trimethaphan.
Hexamethonium The risk or severity of adverse effects can be increased when Sulfanitran is combined with Hexamethonium.
Cyclopentamine The risk or severity of adverse effects can be increased when Sulfanitran is combined with Cyclopentamine.
Methotrexate The protein binding of Methotrexate can be increased when combined with Sulfanitran.
Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Sulfanitran.
Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfanitran.
Cyclosporine The risk or severity of renal failure can be increased when Sulfanitran is combined with Cyclosporine.
Insulin human The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin human.
Insulin lispro The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin lispro.
Insulin glargine The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin glargine.
Insulin pork The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin pork.
Troglitazone The therapeutic efficacy of Troglitazone can be increased when used in combination with Sulfanitran.
Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Sulfanitran.
Sulfisoxazole The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Sulfanitran.
Disopyramide The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfanitran.
Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Sulfanitran.
Metformin The therapeutic efficacy of Metformin can be increased when used in combination with Sulfanitran.
Sulfadiazine The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Sulfanitran.
Rosiglitazone The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Sulfanitran.
Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Sulfanitran.
Quinine The therapeutic efficacy of Quinine can be increased when used in combination with Sulfanitran.
Miglitol The therapeutic efficacy of Miglitol can be increased when used in combination with Sulfanitran.
Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Sulfanitran.
Nateglinide The therapeutic efficacy of Nateglinide can be increased when used in combination with Sulfanitran.
Pentamidine The therapeutic efficacy of Pentamidine can be increased when used in combination with Sulfanitran.
Mifepristone The therapeutic efficacy of Mifepristone can be increased when used in combination with Sulfanitran.
Tolazamide The therapeutic efficacy of Tolazamide can be increased when used in combination with Sulfanitran.
Repaglinide The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfanitran.
Phenformin The therapeutic efficacy of Phenformin can be increased when used in combination with Sulfanitran.
Sulfamethoxazole The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfanitran.
Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Sulfanitran.
Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Sulfanitran.
Gliclazide The therapeutic efficacy of Gliclazide can be increased when used in combination with Sulfanitran.
Tolbutamide The therapeutic efficacy of Tolbutamide can be increased when used in combination with Sulfanitran.
Pioglitazone The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfanitran.
Bromocriptine The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfanitran.
Gliquidone The therapeutic efficacy of Gliquidone can be increased when used in combination with Sulfanitran.
Mitiglinide The therapeutic efficacy of Mitiglinide can be increased when used in combination with Sulfanitran.
Sitagliptin The therapeutic efficacy of Sitagliptin can be increased when used in combination with Sulfanitran.
Sunitinib The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfanitran.
Exenatide The therapeutic efficacy of Exenatide can be increased when used in combination with Sulfanitran.
Mecasermin The therapeutic efficacy of Mecasermin can be increased when used in combination with Sulfanitran.
Pramlintide The therapeutic efficacy of Pramlintide can be increased when used in combination with Sulfanitran.
Glisoxepide The therapeutic efficacy of Glisoxepide can be increased when used in combination with Sulfanitran.
Insulin aspart The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin aspart.
Insulin detemir The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin detemir.
Insulin glulisine The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin glulisine.
Glymidine The therapeutic efficacy of Glymidine can be increased when used in combination with Sulfanitran.
AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Sulfanitran.
Buformin The therapeutic efficacy of Buformin can be increased when used in combination with Sulfanitran.
Vildagliptin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfanitran.
Voglibose The therapeutic efficacy of Voglibose can be increased when used in combination with Sulfanitran.
NN344 The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with NN344.
AMG-222 The therapeutic efficacy of AMG-222 can be increased when used in combination with Sulfanitran.
Bisegliptin The therapeutic efficacy of Bisegliptin can be increased when used in combination with Sulfanitran.
Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfanitran.
Dapagliflozin The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfanitran.
Saxagliptin The therapeutic efficacy of Saxagliptin can be increased when used in combination with Sulfanitran.
Liraglutide The therapeutic efficacy of Liraglutide can be increased when used in combination with Sulfanitran.
Gosogliptin The therapeutic efficacy of Gosogliptin can be increased when used in combination with Sulfanitran.
Linagliptin The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfanitran.
Canagliflozin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfanitran.
Glibornuride The therapeutic efficacy of Glibornuride can be increased when used in combination with Sulfanitran.
Benfluorex The therapeutic efficacy of Benfluorex can be increased when used in combination with Sulfanitran.
Empagliflozin The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfanitran.
Albiglutide The therapeutic efficacy of Albiglutide can be increased when used in combination with Sulfanitran.
Dulaglutide The therapeutic efficacy of Dulaglutide can be increased when used in combination with Sulfanitran.
Lobeglitazone The therapeutic efficacy of Lobeglitazone can be increased when used in combination with Sulfanitran.
Netoglitazone The therapeutic efficacy of Netoglitazone can be increased when used in combination with Sulfanitran.
Rivoglitazone The therapeutic efficacy of Rivoglitazone can be increased when used in combination with Sulfanitran.
Ciglitazone The therapeutic efficacy of Ciglitazone can be increased when used in combination with Sulfanitran.
Lixisenatide The therapeutic efficacy of Lixisenatide can be increased when used in combination with Sulfanitran.
Insulin beef The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin beef.
Insulin degludec The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin degludec.
Insulin peglispro The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hypoglycemia can be increased when Sulfanitran is combined with Insulin tregopil.
Ipragliflozin The therapeutic efficacy of Ipragliflozin can be increased when used in combination with Sulfanitran.
Dutogliptin The therapeutic efficacy of Dutogliptin can be increased when used in combination with Sulfanitran.
Allicin The therapeutic efficacy of Allicin can be increased when used in combination with Sulfanitran.
Tofogliflozin The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Sulfanitran.
Ertugliflozin The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Sulfanitran.
2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Sulfanitran.
Teneligliptin The therapeutic efficacy of Teneligliptin can be increased when used in combination with Sulfanitran.
Omarigliptin The therapeutic efficacy of Omarigliptin can be increased when used in combination with Sulfanitran.
Carmegliptin The therapeutic efficacy of Carmegliptin can be increased when used in combination with Sulfanitran.
Gemigliptin The therapeutic efficacy of Gemigliptin can be increased when used in combination with Sulfanitran.
Anagliptin The therapeutic efficacy of Anagliptin can be increased when used in combination with Sulfanitran.
Evogliptin The therapeutic efficacy of Evogliptin can be increased when used in combination with Sulfanitran.
Sotagliflozin The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Sulfanitran.
Balaglitazone The therapeutic efficacy of Balaglitazone can be increased when used in combination with Sulfanitran.
Remogliflozin etabonate The therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with Sulfanitran.
Carbutamide The therapeutic efficacy of Carbutamide can be increased when used in combination with Sulfanitran.
Guar gum The therapeutic efficacy of Guar gum can be increased when used in combination with Sulfanitran.
Metahexamide The therapeutic efficacy of Metahexamide can be increased when used in combination with Sulfanitran.
Semaglutide The therapeutic efficacy of Semaglutide can be increased when used in combination with Sulfanitran.
Taspoglutide The therapeutic efficacy of Taspoglutide can be increased when used in combination with Sulfanitran.
Englitazone The therapeutic efficacy of Englitazone can be increased when used in combination with Sulfanitran.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 596630
    Authors unspecified: Determination of sulfanitran in animal feeds and pre-mixes. Analyst. 1977 Nov;102(1220):869-72.
  • PMID: 17580695
  • PMID: 12702717
    Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, Borst P: Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44. Epub 2003 Apr 17.
  • PMID: 2759987
    Parks OW: Liquid chromatographic-electrochemical detection screening procedure for six nitro-containing drugs in chicken tissues at low ppb level. J Assoc Off Anal Chem. 1989 Jul-Aug;72(4):567-9.
  • PMID: 19782883
    Ursic D, Berginc K, Zakelj S, Kristl A: Influence of luminal monosaccharides on secretion of glutathione conjugates from rat small intestine in vitro. Int J Pharm. 2009 Nov 3;381(2):199-204. doi: 10.1016/j.ijpharm.2009.03.011. Epub 2009 Mar 19.
  • PMID: 18579149
    Cai Z, Zhang Y, Pan H, Tie X, Ren Y: Simultaneous determination of 24 sulfonamide residues in meat by ultra-performance liquid chromatography tandem mass spectrometry. J Chromatogr A. 2008 Jul 25;1200(2):144-55. doi: 10.1016/j.chroma.2008.05.095. Epub 2008 Jun 8.
  • PMID: 18180270
    Zimmermann C, van de Wetering K, van de Steeg E, Wagenaar E, Vens C, Schinkel AH: Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos. 2008 Apr;36(4):631-40. doi: 10.1124/dmd.107.019620. Epub 2008 Jan 7.
  • PMID: 561053
    Eaves KL, Colvin BM, Hanks AR, Bushway RJ: High pressure liquid chromatographic determination of sulfanitran and dinsed in medicated feeds and premixes. J Assoc Off Anal Chem. 1977 Sep;60(5):1064-6.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul